成孔蛋白Gasdermin E很可能成为改善癌症治疗的有效靶标

2019-04-23 不详 MedSci原创

最新发表的Nature Communications报道,成孔蛋白Gasdermin E在许多癌症中被下调,但是Gasdermin E可以促进细胞死亡,很可能用于抑制肿瘤的生长。

最新发表的Nature Communications报道,成孔蛋白Gasdermin E在许多癌症中被下调,但是Gasdermin E可以促进细胞死亡,很可能用于抑制肿瘤的生长。

使用化疗药物刺激细胞凋亡抗肿瘤时,研究人员发现成孔蛋白gasdermin E不仅在细胞膜上形打孔,也在细胞线粒体膜上打孔,加速了肿瘤细胞凋亡的进程。

敲除gasdermin E后,caspase-3的激活程度显着降低,这表明gasdermin E也可作为细胞凋亡执行蛋白caspase-3的另一个"开启"开关。

研究负责人Emad Alnemri表示:"gasdermin E可以作为区分攻击性肿瘤与不那么激进的肿瘤的标志物......攻击性肿瘤可能没有gasdermin E,但攻击性较小的肿瘤可能更多。"

研究结果还表明,gasdermin E可能是癌症治疗的靶标。据新闻媒体报道,许多肿瘤内的gasdermin E表达被沉默,但化疗药物如地西他滨可重新激活其表达。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1690634, encodeId=b4ba1690634ae, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Thu Sep 19 21:59:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072542, encodeId=9ccc20e2542dc, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Aug 20 12:59:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844280, encodeId=8f45184428033, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Sep 25 03:59:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352839, encodeId=004f135283943, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 25 09:59:00 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
    2019-09-19 okhuali
  2. [GetPortalCommentsPageByObjectIdResponse(id=1690634, encodeId=b4ba1690634ae, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Thu Sep 19 21:59:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072542, encodeId=9ccc20e2542dc, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Aug 20 12:59:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844280, encodeId=8f45184428033, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Sep 25 03:59:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352839, encodeId=004f135283943, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 25 09:59:00 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
    2019-08-20 许安
  3. [GetPortalCommentsPageByObjectIdResponse(id=1690634, encodeId=b4ba1690634ae, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Thu Sep 19 21:59:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072542, encodeId=9ccc20e2542dc, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Aug 20 12:59:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844280, encodeId=8f45184428033, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Sep 25 03:59:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352839, encodeId=004f135283943, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 25 09:59:00 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1690634, encodeId=b4ba1690634ae, content=<a href='/topic/show?id=5c472843a1' target=_blank style='color:#2F92EE;'>#ASD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2843, encryptionId=5c472843a1, topicName=ASD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e8529069357, createdName=okhuali, createdTime=Thu Sep 19 21:59:00 CST 2019, time=2019-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072542, encodeId=9ccc20e2542dc, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Tue Aug 20 12:59:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844280, encodeId=8f45184428033, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Wed Sep 25 03:59:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352839, encodeId=004f135283943, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Apr 25 09:59:00 CST 2019, time=2019-04-25, status=1, ipAttribution=)]
    2019-04-25 zhaojie88